Modelling two-laser asynchronous optical sampling using a single 2-section semiconductor mode-locked laser diode.

We present a theoretical overview and a proposed methodology which demonstrates SLASOPS (single laser asynchronous optical sampling) as a single-laser alternative to the conventional two-laser ASOPS technique. We propose the optical and electronic setup in which SLASOPS may be achieved experimentally with a single 2-section mode-locked laser diode as the pulsed-laser source and simulate how asynchronous optical sampling is generated and detected theoretically. We highlight the technique's ability to provide customizable scan ranges, scan rates and scan resolutions through variation of the imbalance in the interferometer arms and by tuning the repetition rate of the pulsed-laser source, which we present as optical cross-correlations between pulse pairs. We incorporate jitter into the system mathematically to assess the limitations on resolving both intensity and interferometric cross-correlation traces and to investigate the effects of averaging such traces in real-time. Analysis is then carried out on cross-correlation trace amplitude, width, and temporal positioning in order to discuss the technique's ability for deployment in typical optical sampling applications. In particular we note SLASOPS' ability to conduct asynchronous optical sampling using only a single laser, halving both the expense and technical requirements, doing so at megahertz scan rates, and within a spatial precision of just a few microns.

Individualized prescribing portraits to reduce inappropriate initiation of opioid analgesics to opioid naïve patients in primary care: Protocol for a randomized controlled trial.

Background Opioid analgesics are frequently initiated for chronic and acute pain despite weak evidence of benefit, although prescribing rates of some analgesics decreased in the context of the epidemic. In some populations, up to a quarter of opioid naïve persons prescribed opioids for non-cancer pain develop prescription opioid use disorder (OUD). Audit and feedback interventions rely on constructive use of routinely collected data to align professional behaviours and clinical practice with best evidence. These interventions have been shown to help reduce inappropriate initiation. However, effectiveness and acceptability of individualized "portraits" of physicians' prescribing patterns, to reduce inappropriate initiation of opioid analgesics to opioid naïve persons, have not been evaluated. Methods REDONNA is a mixed-methods randomized study testing the effectiveness of individualized prescribing Portraits to reduce inappropriate initiation of opioid analgesics. This intervention to improve safety of opioid prescribing in primary care in British Columbia (BC), Canada involves mailing individual prescribing portraits to an 'early group' of 2604 family physicians, followed in 6 months by a mailing to 2553 family physicians in the 'delayed group'. Primary outcome is number of new opioid prescriptions initiated in opioid naïve people, measured using administrative data from a centralized medication monitoring database covering all prescription opioids dispensed from BC community pharmacies. Secondary endpoints will compare prescribing impact between the two groups. A qualitative sub-study will examine feasibility among a purposive sample of physicians and patients. Discussion This trial provides important evidence on the intervention's potential to steer policy and practice on inappropriate opioid analgesics initiation. Trial registration: The study was registered prospectively on 30 March 2020 at the ISRCTN Register (https://www.isrctn.com/ISRCTN34246811).

Can Linked Electronic Medical Record and Administrative Data Help Us Identify Those Living with Frailty?

INTRODUCTION: Frailty is a complex condition that affects many aspects of patients' wellbeing and health outcomes. OBJECTIVES: We used available Electronic Medical Record (EMR) and administrative data to determine definitions of frailty. We also examined whether there were differences in demographics or health conditions among those identified as frail in either the EMR or administrative data. METHODS: EMR and administrative data were linked in British Columbia (BC) and Manitoba (MB) to identify those aged 65 years and older who were frail. The EMR data were obtained from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) and the administrative data (e.g. billing, hospitalizations) was obtained from Population Data BC and the Manitoba Population Research Data Repository. Sociodemographic characteristics, risk factors, prescribed medications, use and costs of healthcare are described for those identified as frail. RESULTS: Sociodemographic and utilization differences were found among those identified as frail from the EMR compared to those in the administrative data. Among those who were >65 years, who had a record in both EMR and administrative data, 5%-8% (n=191 of 3,553, BC; n=2,396 of 29,382, MB) were identified as frail. There was a higher likelihood of being frail with increasing age and being a woman. In BC and MB, those identified as frail in both data sources have approximately twice the number of contacts with primary care (n=20 vs. n=10) and more days in hospital (n=7.2 vs. n=1.9 in BC; n=9.8 vs. n=2.8 in MB) compared to those who are not frail; 27% (BC) and 14% (MB) of those identified as frail in 2014 died in 2015. CONCLUSIONS: Identifying frailty using EMR data is particularly challenging because many functional deficits are not routinely recorded in structured data fields. Our results suggest frailty can be captured along a continuum using both EMR and administrative data.

Frequency comb metrology with an optical parametric oscillator.

We report on the first demonstration of absolute frequency comb metrology with an optical parametric oscillator (OPO) frequency comb. The synchronously-pumped OPO operated in the 1.5-µm spectral region and was referenced to an H-maser atomic clock. Using different techniques, we thoroughly characterized the frequency noise power spectral density (PSD) of the repetition rate frep, of the carrier-envelope offset frequency fCEO, and of an optical comb line νN. The comb mode optical linewidth at 1557 nm was determined to be ~70 kHz for an observation time of 1 s from the measured frequency noise PSD, and was limited by the stability of the microwave frequency standard available for the stabilization of the comb repetition rate. We achieved a tight lock of the carrier envelope offset frequency with only ~300 mrad residual integrated phase noise, which makes its contribution to the optical linewidth negligible. The OPO comb was used to measure the absolute optical frequency of a near-infrared laser whose second-harmonic component was locked to the F = 2→3 transition of the 87Rb D2 line at 780 nm, leading to a measured transition frequency of νRb = 384,228,115,346 ± 16 kHz. We performed the same measurement with a commercial fiber-laser comb operating in the 1.5-µm region. Both the OPO comb and the commercial fiber comb achieved similar performance. The measurement accuracy was limited by interferometric noise in the fibered setup of the Rb-stabilized laser.

1-GHz harmonically pumped femtosecond optical parametric oscillator frequency comb.

We present the first example of a femtosecond optical parametric oscillator frequency comb harmonically-pumped by a 333-MHz Ti:sapphire laser to achieve a stabilized signal comb at 1-GHz mode spacing in the 1.1-1.6-µm wavelength band. Simultaneous locking of the comb carrier-envelope-offset and repetition frequencies is achieved with uncertainties over 1 s of 0.27 Hz and 5 mHz respectively, which are comparable with those of 0.27 Hz and 1.5 mHz achieved for 333-MHz fundamental pumping. The phase-noise power-spectral density of the CEO frequency integrated from 1 Hz-64 kHz was 2.8 rad for the harmonic comb, 1.0 rad greater than for fundamental pumping. The results show that harmonic operation does not substantially compromise the frequency-stability of the comb, which is shown to be limited only by the Rb atomic frequency reference used.

Furazolidone in chicken: case study of an incident of widespread contamination.

1. Furazolidone, a nitrofuran antibiotic, was prohibited from the use in food-producing animals in the European Union (EU) in 1997. In 2002, the EU restricted the import of poultry meat and aquaculture species from countries where furazolidone residues had been detected. 2. By 2004, however, residues of the side-chain metabolite, 3-amino-2-oxazolidinone (AOZ) of furazolidone, were detected in chicken meat produced in Northern Ireland. 3. With the random spread of positive results across farms of a single integrated organisation, including organically reared flocks, it seemed unlikely that the source of residues was due to illegal use of the drug, but more likely caused by a source of contamination. 4. Potential sources investigated were as follows: furazolidone contamination of feedstuffs, a "hot spot" of furazolidone in poultry houses, contamination occurring within breeding stocks and transferred with the birds to broiler growing houses, and furazolidone contamination of the water supply. 5. Furazolidone contamination was associated with birds reared in houses more than 10 years old. 6. Contamination was traced to the water supply of poultry houses, where un-dissolved furazolidone, legally administered prior to 1997, had settled to the bottom of water storage tanks. It remained un-disturbed until 2004 when the integrator changed the procedure for cleaning water tanks between crops of birds. 7. The use of Proxitane, a hydrogen peroxide disinfectant, caused effervescence within the tank such that small quantities of furazolidone were dissolved, delivered to birds via drinkers and subsequently caused residues in the broiler meat. 8. The environmental impact of the contamination was investigated by testing soil and grass from land adjacent to an organic poultry house to which birds had access. 9. Mechanisms of contamination and how residues may be spread throughout a large integrated poultry system are not restricted to furazolidone. Incidents of contamination are even more likely when using licensed drugs where the drugs may be present on-farm in large quantities.

Residues of nitrofuran antibiotic parent compounds and metabolites in eyes of broiler chickens.

Nitrofuran antibiotic residues in food continue to be of international concern. The finding of sources of semicarbazide (SEM), other than through the misuse of nitrofurazone, present a challenge to the use of SEM as a definitive marker residue for this drug. Detection of intact (parent) nitrofurazone would avoid confusion over the source of SEM residues. Broiler chickens were fed sub-therapeutic nitrofuran-containing diets and their tissues were analysed for parent compounds and metabolites by liquid chromatography coupled with tandem mass spectrometry detection (LC-MS/MS). Depletion half-lives in muscle were longer for tissue-bound metabolite residues, 3.4 days --3-amino-2-oxazolidinone (AOZ), 3-amino-5-morpholinomethyl-2-oxazolidone (AMOZ) -- to 4.5 days (SEM), than total metabolite residues, 2.0 days (AOZ) to 3.2 days (SEM). Metabolite concentrations were higher in eyes than in muscle. Metabolite half-lives in eyes ranged from 8.5 days (1-aminohydantoin (AHD)) to 20.3 days (SEM). Nitrofuran parent compounds were also detected in eyes. Furaltadone was detected in single eyes after 21 days' withdrawal of a 6 mg kg(-1) furaltadone diet. When 50 eyes from broilers containing metabolites in muscle close to the 1 microg kg(-1) minimum required performance level (MRPL) were pooled into single samples, 1.2 ng of furazolidone and 31.1 ng of furaltadone were detected, but nitrofurazone was not detected due to the long depletion half-life of SEM in muscle. Further studies are required to improve LC-MS/MS nitrofurazone sensitivity and refine the sample size necessary to use nitrofurazone detection in pooled eyes as a complement to SEM detection in muscle.

Detection, accumulation and distribution of nitrofuran residues in egg yolk, albumen and shell.

Nitrofuran antibiotics have been banned for use in food-producing animals in many countries, including the European Union, owing to the threat they pose to human health. Research continues into the accumulation of these drugs in animal tissues and into the appropriate methods for their detection. In this study, an LC-MS/MS method is presented for the detection of the parent compounds, furazolidone, nitrofurantoin, furaltadone and nitrofurazone, in eggs. The parent compounds are first extracted into ethyl acetate, fats are removed by partition between acetonitrile and hexane, and the concentrated sample is analysed by LC-MS/MS. Decision limits (CCalpha) for the parents were < or =1 microg kg-1 for all four compounds. Within-day and between-day CVs are well within the limits stated in Commission Decision 2002/657/EC. The method provides an alternative to the testing of side-chain metabolites in eggs, which is particularly important in the case of nitrofurazone, where semicarbazide contamination of food has been attributed to sources other than nitrofurazone use. This method was used together with a method for the detection of the side-chain metabolite compounds, 3-amino-2-oxazolidinone (AOZ), 3-amino-5-morpholinomethyl-1,3-oxazolidin-2-one (AMOZ), 1-amino-hydantoin (AHD) and semicarbazide (SEM), to study the accumulation and distribution of nitrofurans in eggs. Eggs were collected from four groups of hens that had been treated with one of the nitrofurans at a feed concentration of 300 mg kg-1 for 1 week. Parent compounds and metabolites were found in the yolk, albumen and shell. Albumen/yolk ratios for the parent compounds were 0.7, 0.82, 0.83 and 0.31 for furazolidone, furaltadone, nitrofurantoin and nitrofurazone, respectively. Ratios for the side-chain metabolites were 1.02, 1.06, 0.83 and 0.55 for AOZ, AMOZ, AHD and SEM, respectively. However, 50% of the total SEM residues were found in eggshell. This may be significant if eggshell products reach the consumer.

Transfer of nitrofuran residues from parent broiler breeder chickens to broiler progeny.

The use of nitrofuran antibiotics in food-producing animals is prohibited within the EU. Countries in the EU, as well those intending to export food to the EU, must ensure that their products are free from nitrofuran residues. As a result of recent global problems where chicken meat from a wide range of countries has been contaminated with nitrofuran metabolites, an investigation was performed to discover whether or not residues of the nitrofurans might be transferred from parent breeder chickens to their offspring broilers. Four groups of broiler breeders were each treated with one of the nitrofurans: furazolidone, nitrofurazone, nitrofurantoin or furaltadone. Residues of their side-chain metabolites, AOZ, SEM, AHD and AMOZ, were detected in the fertilised eggs at concentrations up to 1567 microg/kg. However, in the chicks that subsequently hatched from these eggs, residue concentrations of SEM, for example, were only found up to 26.6 and 32.5 microg/kg in liver and muscle, respectively, for 1-d-old chicks. Residue concentrations in tissues had fallen below the detection limit of the analytical method for 40-d-old broiler chicks, for all compounds except for semicarbazide (SEM, the nitrofurazone metabolite). Relatively high concentrations of nitrofurans are available to the newly hatched chick through the egg yolk. However, most of these residues are neither utilised nor deposited in the liver or muscle.

Depletion of four nitrofuran antibiotics and their tissue-bound metabolites in porcine tissues and determination using LC-MS/MS and HPLC-UV.

Depletion of the nitrofuran antibiotics furazolidone, furaltadone, nitrofurantoin and nitrofurazone and their tissue-bound metabolites AOZ, AMOZ, AHD and SEM from pig muscle, liver and kidney tissues is described. Groups of pigs were given feed medicated with one of the nitrofuran drugs at a therapeutic concentration (400?mg?kg(-1)) for ten days. Animals were slaughtered at intervals and tissue samples collected for analysis for six weeks following withdrawal of medicated feed. These samples were analysed both for parent nitrofurans (using LC-MS/MS and HPLC-UV), and for tissue-bound metabolites (using LC-MS/MS). The parent drugs were detectable only sporadically and only in pigs subjected to no withdrawal period whatsoever. This confirms the instability of the four major nitrofuran antibiotics in edible tissues. In contrast, the metabolites accumulated to high concentrations in tissues (ppm levels) and had depletion half lives of between 5.5 and 15.5 days. The metabolites of all four drugs were still readily detectable in tissues six weeks after cessation of treatment. This emphasizes the benefits of monitoring for the stable metabolites of the nitrofurans.

The occurrence of nitrofuran metabolites in the tissues of chickens exposed to very low dietary concentrations of the nitrofurans.

The global problem of food products contaminated by residues of the banned carcinogenic nitrofuran drugs has prompted research into how such residues accumulate in tissues. In the study described here, two aspects have been investigated where the nitrofurans accumulate in tissues from chickens exposed to either a dietary or an environmental source of contamination. Twenty groups of broilers were fed a diet containing one of the nitrofurans: furazolidone, nitrofurazone, nitrofurantoin or furaltadone at concentrations of 30, 100, 300, 1000 and 3000 microg kg(-1). At the lowest concentration of furazolidone contamination (0.01% of the therapeutic dose) tissue bound AOZ metabolite residues were detected in liver (1.1 +/- 0.2 microg kg(-1)) and in muscle (0.33 +/- 0.03 microg kg(-1)). Similar results were obtained for AMOZ (0.6 +/- 0.2 microg kg(-1) in liver), the tissue bound metabolite of furaltadone. There was no appreciable accumulation of nitrofurantoin in chicken muscle. The AHD metabolite was not detected in muscle from birds fed nitrofurantoin at either 30 or 100 microg kg(-1). For nitrofurazone the concentrations of the SEM metabolite were higher in muscle than in liver for all dietary concentrations. The potential for a contaminated environment to cause nitrofuran residues in chickens was investigated. Six chickens were placed in a pen that was previously occupied by birds fed a diet containing 3000 microg kg(-1) of furazolidone. After 24 hours' exposure of the chickens to the litter in the pen, AOZ residues of 0.13 +/- 0.04 and 0.10 +/- 0.03 microg kg(-1) were detected in liver and muscle, respectively. The results of both experiments have implications for the poultry industry in trying to eliminate nitrofurans from their production systems, and for regulatory analysts faced with the detection of low concentrations of the drugs, both in tissues and in feedingstuffs.

Evaluation of the residues of furazolidone and its metabolite, 3-amino-2-oxazolidinone (AOZ), in eggs.

The use of furazolidone in food-producing animals is banned within the EU. Detection of the protein-bound side-chain metabolite, 3-amino-2-oxazolidinone (AOZ), in animal tissues is the most effective method of enforcing the ban. The study was undertaken to find out if the same applies to eggs. The concentrations of furazolidone and AOZ in eggs reached a plateau of approximately 360-380 microg kg(-1) by the fourth day of treating birds with 400 mg kg(-1) furazolidone. After a 4-day withdrawal from treatment, intact furazolidone could not be detected. AOZ residues could still be detected up to 21 days following withdrawal from treatment. During treatment, most intact furazolidone residues occur in the albumen. For AOZ, there is a more even distribution of residues between albumen and the yolk. The concentration of furazolidone in egg homogenates stored at -20 degrees C decreases by 44% after 55 days. AOZ residues are stable during this period. From these results, it is clear that AOZ is a more suitable marker residue than the parent compound for monitoring concentrations of the drug in eggs.

Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis.

Angiotensin II upregulates tumor necrosis factor-alpha (TNF-alpha) in the rat kidney with unilateral ureteral obstruction (UUO). In a mouse model of UUO, we found that tubulointerstitial fibrosis is blunted when the TNF-alpha receptor, TNFR1, is functionally knocked out. In this study, we used mutant mice with UUO in which the angiotensin II receptor AT(1a) or the TNF-alpha receptors TNFR1 and TNFR2 were knocked out to elucidate interactions between the two systems. The contribution of both systems to renal fibrosis was assessed by treating TNFR1/TNFR2-double knockout (KO) mice with an angiotensin-converting enzyme inhibitor, enalapril. The increased interstitial volume (Vv(int)) in the C57BI/6 wild-type mouse was decreased in the AT(1a) KO from 32.8 +/- 4.0 to 21.0 +/- 3.7% (P < 0.005) or in the TNFR1/TNFR2 KO to 22.3 +/- 2.1% (P < 0.005). The Vv(int) of the TNFR1/TNFR2 KO was further decreased to 15.2 +/- 3.7% (P < 0.01) by enalapril compared with no treatment. The induction of TNF-alpha mRNA and transforming growth factor-beta1 (TGF-beta1) mRNA in the kidney with UUO was significantly blunted in the AT(1a) or TNFR1/TNFR2 KO mice compared with the wild-type mice. Treatment of the TNFR1/TNFR2 KO mouse with enalapril reduced both TNF-alpha and TGF-beta1 mRNA and their proteins to near normal levels. Also, alpha-smooth muscle actin expression and myofibroblast proliferation were significantly inhibited in the AT(1a) or TNFR1/TNFR2 KO mice, and they were further inhibited in enalapril-treated TNFR1/TNFR2 KO mice. Incapacitating the angiotensin II or the TNF-alpha systems individually leads to partial blunting of fibrosis. Incapacitating both systems, by using a combination of genetic and pharmacological means, further inhibited interstitial fibrosis and tubule atrophy in obstructive nephropathy.

Regulatory problems caused by contamination, a frequently overlooked cause of veterinary drug residues.

The occurrence of violative residues of veterinary medicines and other, unauthorised, drugs in food of animal origin is an issue of popular concern within the European Union. Violations can occur as a result of improper use of a licensed product or through the illegal use of an unlicensed substance. However, a "violative" analytical result does not necessarily mean that abuse has occurred. Contamination of animal feedingstuffs, environmental contamination and animal-to-animal transfer of drugs can also cause residue violations. This paper reviews these inadvertent causes of residues violations in food, and includes data generated using chromatographic and non-chromatographic methods of analysis.

Furazolidone residues in pigs: criteria to distinguish between treatment and contamination.

The use of furazolidone in food-producing animals has been banned in the EU. The ban can most effectively be enforced by monitoring for bound residues containing the 3-amino-2-oxazolidinone (AOZ) moiety. Unlike the parent drug, AOZ residues are stable and can be detected for prolonged periods after cessation of treatment. However, AOZ can be passed from pig-to-pig following brief exposure of unmedicated animals to housing that previously contained medicated pigs. We describe criteria by which a distinction may be drawn between pigs treated illegally with the drug and pigs that contain detectable AOZ residues as a result of exposure to contaminated housing. These criteria are that illegally treated pigs will have a concentration ratio of AOZ in bile:kidney of less than 0.3; while unmedicated pigs will have a concentration ratio of AOZ in bile:kidney of greater than 3.0. Using this criteria, 12 pigs, either treated with the drug or exposed to contaminated housing were analysed in a blind study. The pigs were classified as 'Treated' or 'Contaminated' on the basis of the criteria described above. All 12 pigs were assigned to the correct group. This shows that it is possible to differentiate between furazolidone abuse and contamination.

Comparison of extraction techniques for the recovery of veterinary drug residues from animal tissues.

Four different techniques for the extraction of veterinary drugs were compared. The use of a high speed mixer/emulsifier, an ultrasonic bath, a Stomacher and an end-over-end mixer were used to extract both incurred and fortified residues of chlortetracycline, sulphadiazine and flumequine from chicken muscle. For each drug, similar analytical recoveries from fortified muscle samples were obtained using each of the extraction techniques. However, for each analyte the highest drug concentration detected in incurred samples was obtained following preparation using a mixer/emulsifier extraction. Residue concentrations obtained using sonication, Stomacher or end-over-end mixer procedures were as low as 20% of those obtained using the mixer/emulsifier. This highlights the need to measure both incurred and spiked samples during method validation. A survey of published methods indicated that 75% of laboratories use some form of high-speed homogenization for the extraction of drug residues from tissue. However only 52% reported detection of incurred residues. More than two-thirds of methods that used other forms of extraction did not measure incurred residues. The use of such methods has implications for the statutory detection of veterinary drug residues.

Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy.

Unilateral ureteral obstruction (UUO) results in tubulointerstitial fibrosis of the obstructed kidney. In this study, we report the contribution of tumor necrosis factor-alpha (TNF-alpha) to the fibrosis that develops after ureteral obstruction. Mice in which individual TNF-alpha receptors TNFR1 or TNFR2 had been genetically knocked out were used, and results were compared with mice of C57Bl/6 background after 5 days UUO. Both kidneys were removed and examined histologically for changes in interstitial volume (Vv(int)), collagen IV deposition, alpha-smooth muscle actin (alpha-SMA) matrix score, nuclear factor-kappaB (NF-kappaB) activity, and TNF-alpha mRNA levels. We found that the Vv(int) of contralateral unobstructed kidneys averaged approximately 7% and was indistinguishable among the three genotypes of mice. Vv(int) of ureteral obstructed kidney of C57Bl/6 mice averaged 33 +/- 3.9% after 5 days of UUO. Vv(int) of obstructed kidneys of TNFR1 mice was significantly reduced to 19.4 +/- 3.1%, whereas that of TNFR2 mice was significantly decreased to 25.4% +/- 4.8%. There was a modest but significant difference between Vv(int) of TNFR1 and TNFR2 (P < 0. 047). Both collagen IV and alpha-SMA matrix scores were decreased significantly in obstructed kidney of TNFR1 mouse compared with that of C57Bl/6 and TNFR2 mice. Nuclear extracts prepared from kidney cortex were found to have a significant increase in NF-kappaB binding activity in obstructed kidney compared with contralateral kidney. Individual knockout of the TNFR1 or TNFR2 genes resulted in significantly less NF-kappaB activation compared with the wild type, with TNFR1 being less than TNFR2 knockout. There was a significant increase in TNF-alpha mRNA in the kidney with ureteral obstruction in all three genotypes. TNFR1 knockout displayed a significant reduction in amount of TNF-alpha mRNA induced compared with wild-type or TNFR2 knockout mice. Treatment of TNFR1 knockout mice with an angiotensin converting enzyme inhibitor further decreased Vv(int) and TNF-alpha mRNA induction, suggesting an interaction of ANG II and TNF-alpha systems. These results suggest that TNF-alpha contributes, in part, to changes in interstitial volume, myofibroblast differentiation, and NF-kappaB activation in the kidney during ureteral obstruction. These changes appear to be mediated through both TNFR1 and TNFR2 gene products with effects through the TNFR1 receptor predominating. Furthermore, ANG II appears to stimulate TNF-alpha pathophysiological events leading to renal fibrosis.

Use of liquid chromatography-mass spectrometry in the analysis of residues of antibiotics in meat and milk.

The advent of affordable LC-MS systems has led to a massive increase in a number of publications describing quantitative methods for the analysis and confirmation of veterinary drug residues. The lack of volatility and thermal instability of many antibiotics makes LC-MS the method of choice for their analysis. In the review, analytical methods for the determination of residues of each of the major classes of antibiotics are presented.

Iso- and epi-iso-chlortetracycline and the principal metabolites of chlortetracycline in the hen's egg.

Chlortetracycline (CTC) is a broad spectrum antibiotic, licensed for use without any withdrawal period, in chickens laying eggs intended for human consumption. In the European Union, a maximum residue limit (MRL) in eggs of 200 microgram/kg for the sum of the concentrations of CTC and its 4-epimer (4-epi-CTC) has been established. Two major CTC metabolites have been identified in eggs. These compounds, iso-CTC and 4-epi-iso-CTC, have never previously been shown to be significant products of CTC metabolism in poultry or in any other species. The total amount of CTC present in eggs, as all of the chemical forms measured, can exceed the MRL by anything up to a factor of four (170-820 micrograms/kg).

Comparative in vitro effects of closantel and selected beta-ketoamide anthelmintics on a gastrointestinal nematode and vertebrate liver cells.

PNU-87407 and PNU-88509, beta-ketoamide anthelmintics that are structurally related to each other and to the salicylanilide anthelmintic closantel, exhibit different anthelmintic spectra and apparent toxicity in mammals. The basis for this differential pharmacology was examined in experiments that measured motility and adenosine triphosphate (ATP) levels in larval and adult stages of the gastrointestinal nematode, Haemonchus contortus, and in a vertebrate liver cell line and mitochondria. PNU-87407 and PNU-88509 both exhibited functional cross-resistance with closantel in larval migration assays using closantel-resistant and -sensitive isolates of H. contortus. Each compound reduced motility and ATP levels in cultured adult H. contortus in a concentration- and time-dependent manner; however, motility was reduced more rapidly by PNU-88509, and ATP levels were reduced by lower concentrations of closantel than the beta-ketoamides. Tension recordings from segments of adult H. contortus showed that PNU-88509 induces spastic paralysis, while PNU-87407 and closantel induce flaccid paralysis of the somatic musculature. Marked differences in the actions of these compounds were also observed in the mammalian preparations. In Chang liver cells, ATP levels were reduced after 3 h exposures to > or = 0.25 microM PNU-87407, > or = 1 microM closantel or > or = 10 microM PNU-88509. Reductions in ATP caused by PNU-88509 were completely reversible, while the effects of closantel and PNU-87407 were irreversible. PNU-87407, closantel and PNU-88509 uncoupled oxidative phosphorylation in isolated rat liver mitochondria, inhibiting the respiratory control index (with glutamate or succinate as substrate) by 50% at concentrations of 0.14, 0.9 and 7.6 microM, respectively.